BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 29066508)

  • 21. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
    Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
    Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma.
    Papaxoinis G; Bille A; McLean E; Nonaka D
    Histopathology; 2022 Aug; 81(2):205-214. PubMed ID: 35544410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
    Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
    Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
    Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical correlation of extensive-stage small-cell lung cancer genomics.
    Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
    Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype.
    Hermans BCM; Derks JL; Groen HJM; Stigt JA; van Suylen RJ; Hillen LM; van den Broek EC; Speel EJM; Dingemans AC
    Endocr Connect; 2019 Dec; 8(12):1600-1606. PubMed ID: 31751303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.
    Hiroshima K; Iyoda A; Shibuya K; Haga Y; Toyozaki T; Iizasa T; Nakayama T; Fujisawa T; Ohwada H
    Cancer; 2004 Mar; 100(6):1190-8. PubMed ID: 15022286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?
    Derks JL; Dingemans AC; van Suylen RJ; den Bakker MA; Damhuis RAM; van den Broek EC; Speel EJ; Thunnissen E
    Histopathology; 2019 Mar; 74(4):555-566. PubMed ID: 30485478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
    Shirasawa M; Yoshida T; Takayanagi D; Shiraishi K; Yagishita S; Sekine K; Kanda S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Hamada A; Kohno T; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
    Clin Lung Cancer; 2021 Jul; 22(4):282-291.e6. PubMed ID: 33722498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
    Jones MH; Virtanen C; Honjoh D; Miyoshi T; Satoh Y; Okumura S; Nakagawa K; Nomura H; Ishikawa Y
    Lancet; 2004 Mar; 363(9411):775-81. PubMed ID: 15016488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
    Vrontis K; Economidou SC; Fotopoulos G
    Cancer Invest; 2022 Feb; 40(2):124-131. PubMed ID: 34601985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of the genomic landscape and tumor microenvironment among large cell carcinoma of the lung, large cell neuroendocrine of the lung, and small cell lung cancer.
    Li F; Yang Y; Xu Y; Li K; Song L; Xue Y; Dong D
    Medicine (Baltimore); 2023 Jan; 102(4):e32781. PubMed ID: 36705391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on large cell neuroendocrine carcinoma.
    Hiroshima K; Mino-Kenudson M
    Transl Lung Cancer Res; 2017 Oct; 6(5):530-539. PubMed ID: 29114469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments.
    Yoshimura M; Seki K; Bychkov A; Fukuoka J
    Front Oncol; 2021; 11():671799. PubMed ID: 33968782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
    Dowlati A; Abbas A; Chan T; Henick B; Wang X; Doshi P; Fu P; Patel J; Kuo F; Chang H; Balli D
    JCO Precis Oncol; 2022 Aug; 6():e2200257. PubMed ID: 36044718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of lung large cell neuroendocrine carcinoma.
    Lo Russo G; Pusceddu S; Proto C; Macerelli M; Signorelli D; Vitali M; Ganzinelli M; Gallucci R; Zilembo N; Platania M; Buzzoni R; de Braud F; Garassino MC
    Tumour Biol; 2016 Jun; 37(6):7047-57. PubMed ID: 26943800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
    Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
    J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.